What is adcendo?
Adcendo ApS operates at the intersection of molecular biology and clinical oncology, focusing on the development of antibody-drug conjugates (ADCs). These therapeutic agents are engineered to target specific proteins overexpressed in various cancer forms, offering a more precise mechanism of action compared to traditional chemotherapy. By leveraging proprietary target identification, Adcendo aims to improve patient outcomes in indications where current treatment options remain insufficient. The company's market position is defined by its commitment to high-value, evidence-based drug discovery, positioning it as a key player in the competitive landscape of targeted cancer therapies.
How much funding has adcendo raised?
adcendo has raised a total of $62M across 1 funding round:
Series A
$62M
Series A (2021): $62M with participation from GlideNet Healthcare, RA Capital Management, HealthCap, and Novo Seeds
Key Investors in adcendo
GlideNet Healthcare
A specialized service provider for the acute care marketplace, focusing on integrating value assessment and program execution for hospital systems.
RA Capital Management
A multi-stage investment manager dedicated to evidence-based investing in life science companies, supported by their internal scientific think tank, TechAtlas.
HealthCap
A professional liability insurance provider focused on risk management and quality care initiatives within the senior living and post-acute care sectors.
What's next for adcendo?
With the recent strategic investment, Adcendo is poised to scale its operational capabilities and expand its research infrastructure. The primary focus for the upcoming fiscal periods will be the advancement of its lead ADC candidates into human clinical trials. Furthermore, the company is expected to leverage its partnerships with institutional backers to refine its target discovery platform, potentially broadening its therapeutic reach. As the firm moves deeper into the clinical development lifecycle, the emphasis will likely shift toward data generation and regulatory milestones, which will be critical for future valuation and potential strategic collaborations within the global pharmaceutical industry.
See full adcendo company page
